Advertisement

Topics

GSK confirms £250m deal to sell experimental drug to Dermavent Sciences

05:39 EDT 13 Jul 2018 | Pharmafile

British company GlaxoSmithKline has announced that it will sell the rights to its experimental dermatology drug, tapinarof, to Roivant Sciences’ subsidiary Dermavent Sciences, in a deal worth up to £250 million.

Dermavent made an initial payment of £150 million for the rights to tapinarof, with an agreed future milestone payment of an additional £100 million if the drug meets developmental targets. Upon completion of the deal, Dermavent will hold the global rights to the experimental drug in all countries except China.

read more

Original Article: GSK confirms £250m deal to sell experimental drug to Dermavent Sciences

NEXT ARTICLE

More From BioPortfolio on "GSK confirms £250m deal to sell experimental drug to Dermavent Sciences"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...